12,839 Shares in Enovis Co. (NYSE:ENOV) Purchased by Auxano Advisors LLC

Auxano Advisors LLC purchased a new stake in shares of Enovis Co. (NYSE:ENOV) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 12,839 shares of the company’s stock, valued at approximately $719,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Enovis by 1.1% during the third quarter. Vanguard Group Inc. now owns 4,897,449 shares of the company’s stock worth $258,242,000 after acquiring an additional 51,319 shares in the last quarter. Diamond Hill Capital Management Inc. boosted its position in Enovis by 9.9% during the third quarter. Diamond Hill Capital Management Inc. now owns 2,429,173 shares of the company’s stock valued at $128,090,000 after buying an additional 219,659 shares during the period. DAVENPORT & Co LLC increased its holdings in shares of Enovis by 12.6% in the fourth quarter. DAVENPORT & Co LLC now owns 1,879,425 shares of the company’s stock worth $105,920,000 after buying an additional 210,358 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Enovis by 0.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,031,710 shares of the company’s stock valued at $57,796,000 after acquiring an additional 4,274 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in Enovis by 0.8% during the 3rd quarter. Principal Financial Group Inc. now owns 832,415 shares of the company’s stock valued at $43,893,000 after acquiring an additional 6,353 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Stock Down 1.2 %

NYSE ENOV traded down $0.67 during trading on Tuesday, hitting $55.23. 447,880 shares of the stock traded hands, compared to its average volume of 454,209. Enovis Co. has a 12-month low of $43.04 and a 12-month high of $66.14. The firm has a 50-day simple moving average of $59.80 and a 200-day simple moving average of $55.65. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.16 and a current ratio of 2.43.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.03. Enovis had a negative net margin of 1.95% and a positive return on equity of 3.84%. The company had revenue of $455.00 million for the quarter, compared to analysts’ expectations of $444.34 million. During the same quarter in the previous year, the business posted $0.72 earnings per share. Enovis’s quarterly revenue was up 11.2% on a year-over-year basis. Research analysts predict that Enovis Co. will post 2.58 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ENOV. William Blair initiated coverage on Enovis in a research note on Wednesday, January 3rd. They set an “outperform” rating for the company. Wells Fargo & Company boosted their price objective on shares of Enovis from $73.00 to $79.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Stephens initiated coverage on Enovis in a research note on Tuesday, February 13th. They issued an “overweight” rating and a $72.00 target price on the stock. UBS Group initiated coverage on Enovis in a research note on Monday, January 22nd. They set a “buy” rating and a $75.00 target price on the stock. Finally, Canaccord Genuity Group lifted their target price on shares of Enovis from $73.00 to $75.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $75.43.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.